ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
Rapid and significant improvements in disease clearance with ZORYVE cream with children and adults reaching validated Investigator Global Assessment – Atopic Dermatitis (vIGA-AD) Success at week 4, with significant improvements seen as early as week 1 Demonstrated efficacy and tolerability in treating facial involvement in AD, which affected 42% of trial participants Shown to deliver sustained improvement in disease control for up to 56 weeks of treatment TORONTO March 17, 2025 /CNW/ - Arcutis Canada, Inc., a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, announced today that Health Canada has approved Pr ZORYVE ® (roflumilast cream 0.15%), for the treatment of mild to
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Jefferies Financial Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology MeetingGlobeNewswire
- Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average [Yahoo! Finance]Yahoo! Finance
- Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? [Yahoo! Finance]Yahoo! Finance
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
ARQT
Earnings
- 2/25/25 - Beat
ARQT
Sec Filings
- 3/17/25 - Form 4
- 3/14/25 - Form 144
- 3/13/25 - Form 144
- ARQT's page on the SEC website